JNJ-3792165

Pharmaceutical drug

JNJ-3792165
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

JNJ-3792165 is an investigational pharmaceutical compound developed by Janssen Pharmaceutica, a subsidiary of Johnson & Johnson. It is primarily studied for its potential use in the treatment of various neurological disorders.

Mechanism of Action

JNJ-3792165 is classified as a pharmacological agent that acts on the central nervous system. It functions as a selective antagonist of the NMDA receptor, which is a subtype of glutamate receptor. The NMDA receptor plays a crucial role in synaptic plasticity and memory function. By modulating this receptor, JNJ-3792165 may influence neurotransmission and potentially alleviate symptoms associated with neurological conditions.

Potential Therapeutic Applications

The primary focus of research on JNJ-3792165 is its application in treating neurological disorders such as schizophrenia, depression, and Alzheimer's disease. These conditions are often associated with dysregulation of glutamatergic neurotransmission, and NMDA receptor antagonists like JNJ-3792165 may offer a novel therapeutic approach.

Schizophrenia

In the context of schizophrenia, JNJ-3792165 is being investigated for its ability to mitigate symptoms such as hallucinations, delusions, and cognitive impairment. The compound's action on the NMDA receptor may help restore balance in neurotransmitter systems that are disrupted in schizophrenia.

Depression

JNJ-3792165 is also explored for its potential antidepressant effects. Traditional antidepressants primarily target monoamine neurotransmitters, but NMDA receptor antagonists represent a different mechanism that could benefit patients who do not respond to conventional treatments.

Alzheimer's Disease

In Alzheimer's disease, excessive activation of NMDA receptors is thought to contribute to neurodegeneration. By inhibiting these receptors, JNJ-3792165 may help protect neurons and slow the progression of the disease.

Development and Research

Research on JNJ-3792165 is ongoing, with various clinical trials being conducted to evaluate its safety, efficacy, and pharmacokinetics. The compound is still in the experimental stages, and its approval for clinical use will depend on the outcomes of these studies.

Related Pages

• NMDA receptor antagonist
• Janssen Pharmaceutica
• Schizophrenia
• Depression (mood disorder)
• Alzheimer's disease